Literature DB >> 1364205

CD4+ lymphocyte involvement in ocular Behçet's disease.

D G Charteris1, K Barton, A C McCartney, S L Lightman.   

Abstract

Despite extensive study, the pathogenic mechanisms of Behçet's disease remain uncertain. The ocular inflammation caused by this disease is severe, often causing significant visual loss and, although the nature of the cellular infiltrate has been examined in many of the involved organs, the infiltrating cells in inflamed eyes have not. To investigate the mechanisms involved in perpetuating the ocular inflammation, five enucleated eyes from patients with Behçet's disease were examined by immunohistochemical staining using a panel of monoclonal and polyclonal antibodies. Control eyes from patients with chronic intraocular inflammation from other causes were also examined. Cellular infiltrates were a consistent finding in choroid and periretinal scar tissue, formed almost entirely by mononuclear cells. T lymphocytes were found to predominate (largely the CD4+ subset). B lymphocytes and NK cells were infrequent findings but macrophages were present in significant numbers. No complement or immunoglobulin deposits were found. Infiltrating lymphocytes and macrophages were HLA DR positive. Retinal vascular and retinal pigment epithelium were only occasionally positive. Our findings suggest that cell mediated immunity, rather than immune complex deposition is responsible for the perpetuation of the ocular inflammation in Behçet's disease and that CD4+ T lymphocytes play a central role in this.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1364205     DOI: 10.3109/08916939209148460

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  19 in total

1.  Demyelination of retinal myelinated nerve fibers in Behcet's disease.

Authors:  P S Chavis; K F Tabbara
Journal:  Doc Ophthalmol       Date:  1998       Impact factor: 2.379

2.  Aqueous humor IL-8, IL-10, and VEGF levels in Fuchs' uveitis syndrome and Behçet's uveitis.

Authors:  Mert Simsek; Pinar Cakar Ozdal; Filiz Akbiyik; Mehmet Citirik; Nilufer Berker; Yasemin Ozdamar Erol; Pelin Yilmazbas
Journal:  Int Ophthalmol       Date:  2019-05-07       Impact factor: 2.031

Review 3.  Immunopathology of uveitis.

Authors:  C C Chan; Q Li
Journal:  Br J Ophthalmol       Date:  1998-01       Impact factor: 4.638

4.  The treatment of chronic uveitic macular oedema.

Authors:  A D Dick
Journal:  Br J Ophthalmol       Date:  1994-01       Impact factor: 4.638

5.  Anti-MHC autoimmunity in Behçet's disease: T cell responses to an HLA-B-derived peptide cross-reactive with retinal-S antigen in patients with uveitis.

Authors:  S Kurhan-Yavuz; H Direskeneli; N Bozkurt; Y Ozyazgan; T Bavbek; H Kazokoglu; E Eksioglu-Demiralp; G Wildner; M Diedrichs-Möhring; T Akoglu
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

6.  Molecular analysis of resolving immune responses in uveitis.

Authors:  P I Murray; C D Clay; C Mappin; M Salmon
Journal:  Clin Exp Immunol       Date:  1999-09       Impact factor: 4.330

7.  Comparison of the expression of interferon gamma, IL2, IL4, and lymphotoxin mRNA in experimental autoimmune uveoretinitis.

Authors:  D G Charteris; S L Lightman
Journal:  Br J Ophthalmol       Date:  1994-10       Impact factor: 4.638

8.  Behçet's disease: immunological relevance with arthritis of ankylosing spondylitis.

Authors:  Esin Aktas Cetin; Fulya Cosan; Umut Can Kucuksezer; Sema Bilgic; Yonca Cagatay; Ahmet Gul; Gunnur Deniz
Journal:  Rheumatol Int       Date:  2012-05-11       Impact factor: 2.631

9.  Retrospective study on the effects of immunosuppressive therapy in uveitis associated with rheumatic diseases in Korea.

Authors:  Sang Yeob Lee; Won Tae Chung; Woo Jin Jung; Sung Won Lee
Journal:  Rheumatol Int       Date:  2011-12-24       Impact factor: 2.631

10.  Choroidal thickness alterations in idiopathic acute retinal vasculitis.

Authors:  Ashok Kumar; Vikas Ambiya; Sanjay Kumar Mishra; Mayank Jhanwar
Journal:  Ther Adv Ophthalmol       Date:  2021-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.